{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:31:21Z","timestamp":1793431881099,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["CAMN107ENL04T"],"award-info":[{"award-number":["CAMN107ENL04T"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00228-019-02640-1","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T21:05:11Z","timestamp":1549487111000},"page":"825-829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Feasibility of and patients\u2019 perspective on nilotinib dried blood spot self-sampling"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-3612","authenticated-orcid":false,"given":"Christel C. L. M.","family":"Boons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. W. M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora L.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline G.","family":"Hugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Harry","family":"Hendrikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"issue":"5","key":"2640_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102(5):765\u2013776. \n                    https:\/\/doi.org\/10.1002\/cpt.787","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"2640_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","volume":"53","author":"AJ Wilhelm","year":"2014","unstructured":"Wilhelm AJ, den Burger JC, Swart EL (2014) Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet 53(11):961\u2013973. \n                    https:\/\/doi.org\/10.1007\/s40262-014-0177-7","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"2640_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/FTD.0b013e31819e91ce","volume":"31","author":"PM Edelbroek","year":"2009","unstructured":"Edelbroek PM, van der Heijden J, Stolk LML (2009) Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 31(3):327\u2013336","journal-title":"Ther Drug Monit"},{"issue":"6","key":"2640_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/FTD.0000000000000224","volume":"37","author":"NG Jager","year":"2015","unstructured":"Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH (2015) Dried blood spot self-sampling at home for the individualization of tamoxifen treatment: a feasibility study. Ther Drug Monit 37(6):833\u2013836. \n                    https:\/\/doi.org\/10.1097\/FTD.0000000000000224","journal-title":"Ther Drug Monit"},{"issue":"10","key":"2640_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/jphp.12757","volume":"69","author":"CC Boons","year":"2017","unstructured":"Boons CC, Chahbouni A, Schimmel AM, Wilhelm AJ, den Hartog YM, Janssen JJ, Hendrikse NH, Hugtenburg JG, Swart EL (2017) Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling. J Pharm Pharmacol 69(10):1265\u20131274. \n                    https:\/\/doi.org\/10.1111\/jphp.12757","journal-title":"J Pharm Pharmacol"},{"key":"2640_CR6","doi-asserted-by":"publisher","unstructured":"Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH (2016) The use of dried blood spots for pharmacokinetic monitoring of vemurafenib treatment in melanoma patients. J Clin Pharmacol. \n                    https:\/\/doi.org\/10.1002\/jcph.728","DOI":"10.1002\/jcph.728"},{"key":"2640_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jchromb.2012.07.011","volume":"903","author":"E Kralj","year":"2012","unstructured":"Kralj E, Trontelj J, Pajic T, Kristl A (2012) Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 903:150\u2013156","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"16","key":"2640_CR8","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.4155\/bio.15.101","volume":"7","author":"MV Antunes","year":"2015","unstructured":"Antunes MV, Raymundo S, Wagner SC, Mattevi VS, Vieira N, Leite R, Reginato F, Capra MZ, Fogliatto L, Linden R (2015) DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application. Bioanalysis 7(16):2105\u20132117. \n                    https:\/\/doi.org\/10.4155\/bio.15.101","journal-title":"Bioanalysis"},{"issue":"12","key":"2640_CR9","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/jcph.558","volume":"55","author":"D Wit de","year":"2015","unstructured":"de Wit D, den Hartigh J, Gelderblom H, Qian Y, den Hollander M, Verheul H, Guchelaar HJ, van Erp NP (2015) Dried blood spot analysis for therapeutic drug monitoring of pazopanib. J Clin Pharmacol 55(12):1344\u20131350. \n                    https:\/\/doi.org\/10.1002\/jcph.558","journal-title":"J Clin Pharmacol"},{"key":"2640_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00228-017-2394-0","volume":"74","author":"A Willemsen","year":"2017","unstructured":"Willemsen A, Knapen LM, de Beer YM, Bruggemann RJM, Croes S, van Herpen CML, van Erp NP (2017) Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer. Eur J Clin Pharmacol 74:465\u2013471. \n                    https:\/\/doi.org\/10.1007\/s00228-017-2394-0","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2640_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3851\/IMP2501","volume":"18","author":"W Kromdijk","year":"2013","unstructured":"Kromdijk W, Mulder JW, Smit PM, Ter Heine R, Beijnen JH, Huitema AD (2013) Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study. Antivir Ther 18(6):821\u2013825. \n                    https:\/\/doi.org\/10.3851\/IMP2501","journal-title":"Antivir Ther"},{"key":"2640_CR12","doi-asserted-by":"publisher","first-page":"201918","DOI":"10.1155\/2010\/201918","volume":"2010","author":"AB Leichtle","year":"2010","unstructured":"Leichtle AB, Ceglarek U, Witzigmann H, Gabel G, Thiery J, Fiedler GM (2010) Potential of dried blood self-sampling for cyclosporine c(2) monitoring in transplant outpatients. J Transp Secur 2010:201918. \n                    https:\/\/doi.org\/10.1155\/2010\/201918","journal-title":"J Transp Secur"},{"issue":"5","key":"2640_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","volume":"68","author":"RA Larson","year":"2012","unstructured":"Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD (2012) Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 68(5):723\u2013733","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2640_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","volume":"69","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM (2013) Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol 69(4):813\u2013823","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2640_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/bpb.b15-00103","volume":"38","author":"M Miura","year":"2015","unstructured":"Miura M (2015) Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull 38(5):645\u2013654. \n                    https:\/\/doi.org\/10.1248\/bpb.b15-00103","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"2640_CR16","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496\u20133499. \n                    https:\/\/doi.org\/10.1182\/blood-2006-07-036012","journal-title":"Blood"},{"issue":"5","key":"2640_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3324\/haematol.2011.045666","volume":"97","author":"F Guilhot","year":"2012","unstructured":"Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y (2012) Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. Haematologica 97(5):731\u2013738. \n                    https:\/\/doi.org\/10.3324\/haematol.2011.045666","journal-title":"Haematologica"},{"issue":"suppl_4","key":"2640_CR18","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen J, Hjorth-Hansen H, Richter J, Buske C, Committee EG (2017) Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv41\u2013iv51. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx219","journal-title":"Ann Oncol"},{"issue":"3","key":"2640_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93(3):442\u2013459. \n                    https:\/\/doi.org\/10.1002\/ajh.25011","journal-title":"Am J Hematol"},{"key":"2640_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1471-2407-14-247","volume":"14","author":"CC Boons","year":"2014","unstructured":"Boons CC, Swart EL, Timmers L, van de Ven PM, Janssen JJ, Hugtenburg JG (2014) Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia. BMC Cancer 14:247","journal-title":"BMC Cancer"},{"issue":"2","key":"2640_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1432-2277.2007.00584.x","volume":"21","author":"CY Cheung","year":"2008","unstructured":"Cheung CY, van der Heijden J, Hoogtanders K, Christiaans M, Liu YL, Chan YH, Choi KS, van de Plas A, Shek CC, Chau KF, Li CS, van Hooff J, Stolk L (2008) Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl Int 21(2):140\u2013145. \n                    https:\/\/doi.org\/10.1111\/j.1432-2277.2007.00584.x","journal-title":"Transpl Int"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02640-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02640-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02640-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T19:11:04Z","timestamp":1581016264000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02640-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2640"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02640-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"10 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J.J.W.M. Janssen is an advisory board member for Abbvie, Incyte, Jazz Pharmaceuticals, and Pfizer and has received research support funding from Novartis and Bristol Myers Squibb and speaker\u2019s fees from Incyte and Pfizer. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Medical Ethics review board of Amsterdam University Medical Centers (location VUmc, Amsterdam) (2013.035), as well as the ethical boards of each participating center. All procedures performed were in accordance with the ethical standards of the Medical Ethics review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}